Pharsight

Pomalyst patents expiration

POMALYST's oppositions filed in EPO
Can you believe POMALYST received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8828427 BRISTOL Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Jun, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5635517 BRISTOL Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines
Jul, 2016

(7 years ago)

US6476052 BRISTOL Isoindolines, method of use, and pharmaceutical compositions
Jul, 2016

(7 years ago)

US5653517 BRISTOL Process and system for determination of friction/slip characteristics of road vehicle tires
Jul, 2016

(7 years ago)

US6316471 BRISTOL Isoindolines, method of use, and pharmaceutical compositions
Aug, 2016

(7 years ago)

US8158653 BRISTOL Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline
Aug, 2016

(7 years ago)

US8204763 BRISTOL Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
Aug, 2018

(5 years ago)

US6908432 BRISTOL Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
Aug, 2018

(5 years ago)

US6045501 BRISTOL Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
Aug, 2018

(5 years ago)

US8589188 BRISTOL Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
Aug, 2018

(5 years ago)

US6561976 BRISTOL Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
Aug, 2018

(5 years ago)

US6561977 BRISTOL Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
Oct, 2020

(3 years ago)

US8626531 BRISTOL Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
Oct, 2020

(3 years ago)

US8315886 BRISTOL Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
Oct, 2020

(3 years ago)

US6755784 BRISTOL Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
Oct, 2020

(3 years ago)

US6315720 BRISTOL Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
Oct, 2020

(3 years ago)

US8735428 BRISTOL Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
May, 2023

(1 year, 30 days ago)

US8673939 BRISTOL Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
May, 2023

(1 year, 30 days ago)

US8735428

(Pediatric)

BRISTOL Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Nov, 2023

(6 months ago)

US8673939

(Pediatric)

BRISTOL Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Nov, 2023

(6 months ago)

US8198262 BRISTOL Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Jun, 2025

(1 year, 3 days from now)

US8198262

(Pediatric)

BRISTOL Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Dec, 2025

(1 year, 6 months from now)

US10555939 BRISTOL Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
May, 2030

(5 years from now)

US9993467 BRISTOL Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
May, 2030

(5 years from now)

US10555939

(Pediatric)

BRISTOL Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Nov, 2030

(6 years from now)

US9993467

(Pediatric)

BRISTOL Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Nov, 2030

(6 years from now)

US8828427

(Pediatric)

BRISTOL Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Dec, 2031

(7 years from now)

Pomalyst is owned by Bristol.

Pomalyst contains Pomalidomide.

Pomalyst has a total of 27 drug patents out of which 19 drug patents have expired.

Expired drug patents of Pomalyst are:

  • US5635517
  • US6476052
  • US5653517
  • US6316471
  • US8158653
  • US8204763
  • US6908432
  • US6045501
  • US8589188
  • US6561976
  • US6561977
  • US8626531
  • US8315886
  • US6755784
  • US6315720
  • US8735428
  • US8673939
  • US8735428*PED
  • US8673939*PED

Pomalyst was authorised for market use on 08 February, 2013.

Pomalyst is available in capsule;oral dosage forms.

Pomalyst can be used as use of pomalidomide while preventing the exposure of a fetus or other contraindicated individual to pomalidomide, use of pomalidomide for the treatment of multiple myeloma, use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy, use of pomalidomide to inhibit the secretion of pro-inflammation cytokines, including tumor necrosis factor alpha.

Drug patent challenges can be filed against Pomalyst from 14 November, 2026.

The generics of Pomalyst are possible to be released after 21 December, 2031.

Drug Exclusivity Drug Exclusivity Expiration
M(M-14) Nov 20, 2023
Orphan Drug Exclusivity(ODE-297) May 14, 2027
Orphan Drug Exclusivity(ODE-296) May 14, 2027
Pediatric Exclusivity(PED) Nov 14, 2027
New Indication(I-707) Apr 23, 2018
Orphan Drug Exclusivity(ODE-43) Feb 08, 2020
Orphan Drug Exclusivity(ODE) Feb 08, 2020
New Chemical Entity Exclusivity(NCE) Feb 08, 2018

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using POMALIDOMIDE ingredient

NCE-1 date: 14 November, 2026

Market Authorisation Date: 08 February, 2013

Treatment: Use of pomalidomide to inhibit the secretion of pro-inflammation cytokines, including tumor necrosis factor alpha; Use of pomalidomide for the treatment of multiple myeloma; Use of pomalidomide while ...

Dosage: CAPSULE;ORAL

How can I launch a generic of POMALYST before it's drug patent expiration?
More Information on Dosage

POMALYST family patents

Family Patents